When it comes to the sizzling hot topic of carcinogenesis and diagnostic radiation, it is crucial to differentiate hypothesis from scientific fact, maintain a sober mind, and separate science from politics and economics.
When it comes to the sizzling hot topic of carcinogenesis and diagnostic radiation, it is crucial to differentiate hypothesis from scientific fact, maintain a sober mind, and separate science from politics and economics.
That's the view of Dr. Michael Brant- Zawadzki, medical director for neurosciences at Hoag Memorial Hospital in Newport Beach, California, and an adjunct clinical professor of radiology at Stanford University, in Stanford, California. During the W.C. Roentgen honorary lecture at the ECR, he urged congress attendees to assure the appropriateness of studies, standardize safe dose levels, use the lowest acceptable dose, and introduce a quality assurance process, including recording cumulative doses in a patient's file.
“Someone who comes in with a stroke could die today. But if they are worried about a cancer 30 years from now, they may refuse a lifesaving scan,” Brant- Zawadzki said.
Dr. James Thrall, chief radiologist at Massachusetts General Hospital in Boston, Massachusetts, had made the same statement in Tuesday's edition of The Washington Post.
The risk to patients of radiation dose is evaluated in terms of effective dose as defined by the International Commission on Radiological Protection, Brant- Zawadzki said. Effective dose combines the absorbed dose and a weighting factor related to the radiosensitivity of each organ exposed. Effective dose allows for comparison of various sources and can be calculated for standard body configurations, though not easily for individual patients. The unit of effective dose measurement is the Sievert (Sv).
He gave some ballpark figures for the effective dose of selected examinations: head CT,1 to 2 mSv; chest CT, 5 to 7 mSv; abdominal and pelvic CT, 8 to 11 mSv; diagnostic coronary angiogram, 3 to 30 mSv; SPECT thallium, 25 mSv; SPECT sestamibi 12 mSv; and coronary CT angiogram, 6 to 13 mSv.
“In CT, the science of diagnostic radiation and carcinogenesis has recently become very embroiled in my country, and I'm sure in Europe as well, in the politics and economics of overutilization of this rather expensive technology,” he said.
Radiation injury is either deterministic, which occurs only above a threshold dose, or stochastic, which assumes no threshold. In the former, a degree of injury is related to the dose, and in the latter, the probability of injury increases with dose. Radiation-induced hair loss can result from perfusion CT and a prolonged neuro-interventional procedure with angiography, for example. The top of Brant-Zawadzki's own hands have no hair, presumably due to exposure, he said.
He said it is worth remembering, however, that a major decline in cancer mortality has occurred in the U.S. over the past 50 years, even though cancer incidence has remained relatively stable. This suggests that improvements in cancer detection, treatment, and/or prevention have reduced the risk of cancer-related death.
In some regions, radiation is considered to have a positive impact on health, Brant-Zawadzki said. Bad Gastein, in Switzerland, is one of Europe's leading spa resorts, with 17 thermal springs. The apparent secret of its success is radon, an inert gas producing mildly radioactive emissions. It has a healing, regenerative effect on tissue, and stimulates the metabolic processes. The list of therapeutic indications include rheumatic, arthritic, and scoliotic disease, spinal and disc problems, fertility and potency problems, age-related complaints, and certain metabolic diseases.
Brant-Zawadzki also spoke about the case of Tsutomu Yamaguchi, who was the last double atomic bomb survivor. He was badly burned in Hiroshima, and three days later was in Nagasaki when the second bomb exploded. He lived to be 93, and died of stomach cancer in January of this year.
Furthermore, in the U.S., background radiation in three mountain states is three times that of three gulf states, but the cancer mortality rate is 25% higher in the gulf states, he said.
A version of this article appeared in the 2010 ECR Today newspaper.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare to Launch PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.